You are here

Article Text

Article menu
Download PDFPDF
PostScript
Letters
Authors' response
  1. HH Fidder1,
  2. K van de Steen2,
  3. G van Assche3,
  4. P Rutgeerts3,
  5. S Vermeire3
  1. 1Department of Gastroenterology, Leiden University Hospital, Leiden, The Netherlands
  2. 2Department of Electrical Engineering and Computer Science, Montefiore Institute, University of Liege, Belgium
  3. 3University Hospital Gasthuisberg, Leuven, Belgium
  1. Correspondence to Dr H H Fidder, Department of Gastroenterology, Leiden University Hospital, Albinusdreef 2, 2333ZA Leiden, The Netherlands; hermafidder{at}hotmail.com

https://doi.org/10.1136/gut.2009.204438

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We thank Dr Targownik for the interest in our paper and would like to respond to her comments1 on a possible immortal time bias that our study may contain. Immortal time refers to cohort follow-up time in a time-to-event analysis during which the outcome under study could not occur, due to design or because of the exposure definition itself. In our study, the patients in the infliximab group remained event free, by definition.2 In particular, they had to be alive until …

    View Full Text

    Footnotes

    • Linked articles 186445.

    • Competing interests None to declare.

    • Provenance and peer review Not commissioned; externally peer reviewed.

    Linked Articles